Literature DB >> 16373423

Sex-dependent effect of melatonin on systemic erythematosus lupus developed in Mrl/Mpj-Faslpr mice: it ameliorates the disease course in females, whereas it exacerbates it in males.

Antonio J Jimenez-Caliani1, Silvia Jimenez-Jorge, Patrocinio Molinero, Jose M Fernandez-Santos, Ines Martin-Lacave, Amalia Rubio, Juan M Guerrero, Carmen Osuna.   

Abstract

In this study, the effect of chronic administration of melatonin on MRL/MpJ-Fas(lpr) mice has been studied. These mice spontaneously develop an autoimmune disease that has many features resembling human systemic lupus erythematosus. In fact, histological studies showed that all female mice and most male mice exhibited glomerular abnormalities, arteritic lesions, and cellular interstitial inflammatory infiltrate ranging from mild to severe patterns. Treatment with melatonin improved the histological pattern in females and worsened it in males. Moreover, female mice treated with melatonin showed a diminution of titers of total serum IgG, IgM, and anti-double-stranded DNA and anti-CII autoantibodies; a decrease in proinflammatory cytokines (IL-2, IL-6, interferon-gamma, TNF-alpha, and IL-1beta), an increase in antiinflammatory cytokines (IL-10), and a decrease in nitrite/nitrate. In male mice, treatment with melatonin exhibited the opposite effect, worsening all the immunological parameters with an elevation of titers of autoantibodies and a prevalence of proinflammatory vs. antiinflammatory cytokines. Similar results were obtained when lymphocytes from spleen and lymph nodes were cultured. Again, melatonin treatment in females decreased proinflammatory cytokines and increased antiinflammatory cytokines produced by lymphocytes; in males, the effect was the opposite. These findings suggest that melatonin action in MRL/MpJ-Fas(lpr) mice is gender dependent, probably through modulation and inhibition of sex hormones.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16373423     DOI: 10.1210/en.2005-0648

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

Review 1.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

2.  Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.

Authors:  Svetlana Karakhanova; Julia Link; Moritz Heinrich; Ivan Shevchenko; Yuhui Yang; Matthias Hassenpflug; Henriette Bunge; Katharina von Ahn; Ramona Brecht; Andreas Mathes; Caroline Maier; Viktor Umansky; Jens Werner; Alexandr V Bazhin
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

3.  Darkness hormone or daylight hormone in women with systemic lupus erythematosus?

Authors:  Melek Bilgin; Adem Keskin; Recai Aci; Hatice Sule Baklacioglu; Mukadder Arslanbek Erdem
Journal:  Clin Rheumatol       Date:  2022-09-20       Impact factor: 3.650

Review 4.  Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development.

Authors:  May Y Choi; Karen H Costenbader
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

5.  Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice.

Authors:  Ling-Ling Zhou; Wei Wei; Jun-Feng Si; Dong-Ping Yuan
Journal:  Mediators Inflamm       Date:  2010-07-20       Impact factor: 4.711

6.  Decreased daily melatonin levels in women with systemic lupus erythematosus - a short report.

Authors:  Ralitsa Robeva; Dobromir Tanev; Georgi Kirilov; Milena Stoycheva; Analia Tomova; Philip Kumanov; Rasho Rashkov; Zlatimir Kolarov
Journal:  Balkan Med J       Date:  2013-09-01       Impact factor: 2.021

7.  Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple Sclerosis.

Authors:  Hanin Abdulbaset Abo Taleb; Badrah Saeed Alghamdi
Journal:  J Mol Neurosci       Date:  2019-11-11       Impact factor: 3.444

8.  Therapeutic applications of melatonin.

Authors:  Ifigenia Kostoglou-Athanassiou
Journal:  Ther Adv Endocrinol Metab       Date:  2013-02       Impact factor: 3.565

Review 9.  Melatonin: buffering the immune system.

Authors:  Antonio Carrillo-Vico; Patricia J Lardone; Nuria Alvarez-Sánchez; Ana Rodríguez-Rodríguez; Juan M Guerrero
Journal:  Int J Mol Sci       Date:  2013-04-22       Impact factor: 5.923

Review 10.  Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases.

Authors:  Gu-Jiun Lin; Shing-Hwa Huang; Shyi-Jou Chen; Chih-Hung Wang; Deh-Ming Chang; Huey-Kang Sytwu
Journal:  Int J Mol Sci       Date:  2013-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.